Lazertinib vs Osimertinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Lazertinib
Marketed by Johnson & Johnson and partners
NCT04248829 · Phase 3 · completed
The trial randomized 393 participants to lazertinib or an active gefitinib control with double-blind treatment. Its primary clinical endpoint, investigator-assessed progression-free survival, was met: median 20.6 vs 9.7 months (HR 0.45, 95% CI 0.34 to 0.58; P < .001; PMID 37379502).
Next expected readout: December 2026 · NCT05463224 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46) (met)
Result source: NCT04487080
Osimertinib · Tagrisso
Marketed by AstraZeneca
NCT02151981 · Phase 3 · completed
The trial was randomized and actively controlled, with 279 patients receiving osimertinib and 140 receiving platinum-based chemotherapy, but treatment assignment was not blinded. Its primary clinical endpoint, investigator-assessed progression-free survival, favored osimertinib significantly (hazard ratio 0.30; p<0.001), supporting moderate-strength evidence rather than the strongest level because the study was open-label.
Next expected readout: November 2026 · NCT05998993 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6) (met)
Result source: NCT02151981
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lazertinib | Osimertinib |
|---|---|---|
| PFS, median | 20.6 vs 9.7vs GefitnibNCT042488296 other results
| 19.5 vs 22.0vs GefitinibNCT028568931 other result
|
| OS, median | 9.1bNCT040753961 other result
| —Not posted · NCT05015608 |
| ORR | 76% vs 76.1%vs GefitnibNCT042488292 other results
| 76%bNCT02789345 |
| Duration of response, median | 19.4 vs 8.3vs GefitnibNCT042488291 other result
| 13.4bNCT02789345 |
PFS, median
- Lazertinib
- 20.6 vs 9.7vs GefitnibNCT04248829
6 other results
- 23.7 vs 16.6 NCT04487080
- 18.5 vs 16.6 NCT04487080
- 8.3 vs 4.2 NCT04988295
- 6.3 vs 4.2 NCT04988295
- 3.1 NCT04075396
- 4.2 NCT04075396
- Osimertinib
- 19.5 vs 22.0vs GefitinibNCT02856893
1 other result
- 11.0 NCT02789345
OS, median
- Lazertinib
- 9.1bNCT04075396
1 other result
- 7.7 NCT04075396
- Osimertinib
- —Not posted · NCT05015608
ORR
- Lazertinib
- 76% vs 76.1%vs GefitnibNCT04248829
2 other results
- 26.7% NCT04075396
- 7.7% NCT04075396
- Osimertinib
- 76%bNCT02789345
Duration of response, median
- Lazertinib
- 19.4 vs 8.3vs GefitnibNCT04248829
1 other result
- 2.8 NCT04075396
- Osimertinib
- 13.4bNCT02789345
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. Lazertinib: 9 of 9 rows · Osimertinib: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lazertinib Rows use multiple source trials | Osimertinib Rows use multiple source trials |
|---|---|---|
| Disease Control responder rate · % of participants No placebo or comparator arm | 60% (n=15)240 mga,b,c,d,e NCT04075396 · Phase 1/2 · registry result, not featured evidence show 1 more dose53.8% (n=13)320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence | 92% (n=25)b,c,d,e NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Duration of Response time to event · months No placebo or comparator arm | NA months240 mga,b,c,d,e NCT04075396 · Phase 1/2 · registry result, not featured evidence show 1 more dose2.8 months320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence | 13.37 monthsb,c,d,e NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| ORR responder rate · % of participants No placebo or comparator arm | 26.7% (n=15)240 mga,b,c,d,e NCT04075396 · Phase 1/2 · registry result, not featured evidence show 1 more dose7.7% (n=13)320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence | 76% (n=25)b,c,d,e NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Overall Survival time to event · months No placebo or comparator arm | 9.1 months240 mga,b,c,d,e NCT04075396 · Phase 1/2 · registry result, not featured evidence show 1 more dose7.7 months320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence | NA monthsb,c,d,e NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 3.1 months240 mga,b,c,d,e NCT04075396 · Phase 1/2 · registry result, not featured evidence show 1 more dose4.2 months320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence | 11.04 monthsb,c,d,e NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Dropout rate | 44.9%240 mgf NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 6 more results78.1%Experimental: Arm A (Open-label): NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 75%Experimental: Arm C (Double-blind) NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 74.5%Main Study: Arm A: Lazertinib + Am NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 80.2%Main Study: Arm C: Amivantamab + C NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —240 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence | 62.3%g NCT02856893 · Phase 2 · registry result, not featured evidence show 2 more results100%Arm A: Ramucirumab + Osimertinib NCT02789345 · Phase 1 · registry result, not featured evidence · combination 77.3%Cohort A: Ramucirumab + Osimertini NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 9.7%240 mgf NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 6 more results—Experimental: Arm A (Open-label): NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Experimental: Arm C (Double-blind) NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Main Study: Arm A: Lazertinib + Am NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Main Study: Arm C: Amivantamab + C NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —240 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence —320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence | 3.8%g NCT02856893 · Phase 2 · registry result, not featured evidence show 2 more results0%Arm A: Ramucirumab + Osimertinib NCT02789345 · Phase 1 · registry result, not featured evidence · combination 4.5%Cohort A: Ramucirumab + Osimertini NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 26%240 mgf NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 6 more results48.7%Experimental: Arm A (Open-label): NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 35.2%Experimental: Arm C (Double-blind) NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 52.1%Main Study: Arm A: Lazertinib + Am NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 32.3%Main Study: Arm C: Amivantamab + C NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 66.7%240 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence 46.2%320 mg NCT04075396 · Phase 1/2 · registry result, not featured evidence | 17%g NCT02856893 · Phase 2 · registry result, not featured evidence show 2 more results33.3%Arm A: Ramucirumab + Osimertinib NCT02789345 · Phase 1 · registry result, not featured evidence · combination 36.4%Cohort A: Ramucirumab + Osimertini NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 240 mgf paraesthesia 39.3% rash 36.2% pruritus 26.5% NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 6 more resultsparonychia 68.4% infusion related reaction 62% rash 61.8% NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 rash 44.6% diarrhoea 31.9% paronychia 28.6% NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 neutropenia 65.8% thrombocytopenia 59.3% infusion related reaction 54% NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 infusion related reaction 56.9% neutropenia 56.2% nausea 44.6% NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 240 mg anaemia 46.7% diarrhoea 46.7% aspartate aminotransferase increased 26.7% NCT04075396 · Phase 1/2 · registry result, not featured evidence 320 mg nausea 61.5% diarrhoea 53.8% arthralgia 23.1% NCT04075396 · Phase 1/2 · registry result, not featured evidence | g diarrhea 50.9% dry skin 41.5% weight loss 35.8% NCT02856893 · Phase 2 · registry result, not featured evidence show 2 more resultscough 100% diarrhoea 100% arthralgia 66.7% NCT02789345 · Phase 1 · registry result, not featured evidence · combination diarrhoea 63.6% hypertension 63.6% decreased appetite 40.9% NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 1 versus Phase 1/2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eThe assessment timepoint is not available for both results.
- fPopulation comparability has not been reviewed for 2 of these studies.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lazertinib
show 1 more result
Osimertinib
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lazertinib's landscape · Osimertinib's landscape